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Abstract: 
 
The Safety Pharmacology Society (SPS) conducted an industry survey in 2015 to identify 
industry practices as they relate to central, peripheral and autonomic nervous system („CNS‟) 
drug safety testing. One hundred fifty-eight (158) participants from Asia (16%), Europe (20%) 
and North America (56%) responded to the survey. 52% of participants were from 
pharmaceutical companies (>1,000 employees). Oncology (67%) and neurology/psychiatry 
(66%) were the most frequent target indications pursued by companies followed by 
inflammation (48%), cardiovascular (43%), metabolic (39%), infectious (37%), orphan (32%) 
and respiratory (29%) diseases.  Seizures (67% of participants), gait abnormalities (67%), 
tremors (65%), emesis (56%), sedation (52%) and salivation (47%) were the most commonly 
encountered CNS issues in pre-clinical drug development while headache (65%), 
emesis/nausea (60%), fatigue (51%) and dizziness (49%) were the most frequent issues 
encountered in Phase I clinical trials. 54% of respondents reported that a standard battery of 
tests applied to screen drug candidates was the approach most commonly used to address non-
clinical CNS safety testing. A minority (14% of all participants) reported using 
electroencephalography (EEG) screening prior to animal inclusion on toxicology studies. The 
most frequent group size was n=8 for functional observation battery (FOB), polysomnography 
and seizure liability studies. FOB evaluations were conducted in a dedicated room (78%) by 
blinded personnel (66%) with control for circadian cycle (55%) effects (e.g., dosing at a 
standardized time; balancing time of day across treatment groups). The rat was reported as the 
most common species used for seizure liability, nerve conduction and drug-abuse liability 
testing.  
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1. Introduction 
With 41 new FDA approved drugs, 2014 was a greater than average year for the 
pharmaceutical and biotechnology industry (Anon. 2015). This article focuses on CNS drug 
safety testing, the dynamics between development and Safety Pharmacology methods and 
strategic approaches that have been taken to garner marketing authorization of a new molecular 
entity (NME) under New Drug Applications (NDAs) or as new therapeutic biologic under a 
Biologics License Application (BLA). The aging population has benefited from a moderate but 
progressive increase in drug development efforts for neurological indications (Melnikova, 2010) 
and the CNS drug market is forecast to grow to $81.8 billion in 2015 (BCC Research, 2010). 
Despite this growth to become the 2nd most important therapeutic indication in drug 
development, CNS indications present a challenge since CNS drugs are reported to take longer 
to get to market and their attrition rate is greater than other therapeutic indications (Palmer & 
Alavijeh, 2012).  
Market size and level of unmet need determine the clinical importance of drug 
development within a given therapeutic area which, in turn, reflects upon non-clinical 
professional disciplines such as Safety Pharmacology (SP). In general terms, although drug 
approval rates appear to have increased, drug attrition remains a major hurdle in 
pharmaceutical development (Moreno & Pearson, 2013; Hay et al., 2014; Cook et al., 2014; 
Waring et al., 2015). A tendency towards an increased failure rate in Phase 3 clinical trials due 
to safety issues has been reported over a 5 year period (Arrowsmith & Miller, 2013). Oncology 
remains the largest therapeutic market, with sales exceeding US$100 billion in 2014 after a 
double digit increase in the previous year (Mullard, 2015). In oncology, neurological adverse 
effects remain one of the most frequent cause of drug failure (Valentin & Hammond, 2008; Cook 
et al., 2014), second only to cardiac adverse effects.  
Although non-clinical cardiac SP assessment models and testing strategies have been 
extensively evaluated (Porsolt et al., 2002; Pugsley et al., 2009; Valentin et al., 2010; Authier et 
al., 2010; Vargas et al., 2015; Klein & Redfern, 2015), only limited information is available with 
respect to CNS adverse effect testing strategy and practices. At the more granular level, there 
are comprehensive reviews of non-clinical CNS models for seizure (Bassett et al., 2014; Easter 
et al., 2009; Metea et al., 2015; Fonck et al., 2015) and drug abuse liabilities (Kallman, 2015; 
Moser et al., 2010; Porsolt et al., 2002‟ O‟Connor et al., 2011), with consideration of specific 
screening models for seizure (Authier et al., 2009; Koseki et al., 2014), sleep (Authier et al., 
2014) and peripheral nerve function (Zotova & Arezzo, 2013). However, current industry 
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practices and trends as they relate to the use of these models in drug development are not well 
characterized (Lindgren et al., 2008). 
In view of these considerations, a survey was undertaken by the SPS to evaluate current 
(defined as during the last 5 years) industry practices for CNS drug SP testing, and the present 
paper reports the findings. 
2. Results 
All results are presented as the percentage of total response rate per question, as percentage of 
total number of scientists that responded to each question or number of responding scientists. 
2.1 Study Survey Demographics 
Scientists (n=158) from various fields of expertise (Fig. 1A) and location (Fig. 1B) participated in 
the survey which represented a response rate of 35.3% (158 out of 447 invited). A 
predominance of participants from North America was inevitable owing to the greater proportion 
of scientists from this geographical region in the population solicited to take this survey. 
Participants were distributed between diverse organization types (Fig. 1C) and sizes (Fig. 1D), 
with more than half from larger companies (>1000 employees). As a result, it is expected that 
larger companies have contributed multiple respondents from the same organization. 
Consequently, the results from the survey predominantly reflect practices and perceptions of 
individuals working in larger institutions.  The survey identified some interesting peripheral facts, 
such as the primary therapeutic areas that were targeted by the companies employing survey 
participants. Oncology (67%) and neurology/psychiatry (66%) followed by inflammation (48%), 
cardiovascular (43%), metabolic (38%), infectious (37%), orphan (32%) and respiratory (29%) 
diseases were the most frequent target therapeutic areas reported (Fig. 1E).  
 
2.2. Drug SP Testing for the CNS: Survey results 
Over the last 5 years seizures (67% of participants), gait abnormalities (67%), tremors (65%), 
emesis (56%), sedation (52%) and salivation (47%) were the most commonly encountered CNS 
issues in pre-clinical drug development (Figure 2), whereas headache (65%), emesis/nausea 
(60%), fatigue (51%) and dizziness (49%) were the most frequent issues encountered in Phase 
I clinical trials (Figure 3). A minority (14% of all participants) reported using pre-study EEG 
screening of individual animals prior to inclusion in general toxicology studies. A standard 
battery of tests applied to screen all drug candidates was the approach that best described the 
strategy used by the company for 54% of participants, whereas 37% selected issue resolution 
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with tests based on observations from toxicology screening and scientific considerations as the 
most representative approach used in their company.  
In the last 5 years, various CNS assessment technologies and models had been used by 
participants including gait analysis (45%), elevated plus maze anxiety test (35%), 
electroretinography (32%), visual acuity (i.e., optomotor reflex) (20%) or pica as a model of 
nausea (14%). Most participants (82%) had not received regulatory feedback on their CNS 
safety testing strategy. Of the 18% that had received regulatory feedback, comments on drug 
abuse liability testing were the most frequent.  
2.2.1 Functional Observation Battery (FOB)/Modified Irwin Test 
Survey questions treated FOB and Modified Irwin tests together. Scientific literature is available 
for an in-depth understanding of these assays (Gauvin et al., 1997; Himmel, 2008; Redfern et 
al., 2005). A majority (79%) of participants had conducted or interpreted FOB/Irwin test results 
in the last 5 years. From this subgroup, FOB/Irwin tests were most often conducted in rats 
(96%) and mice (36%) followed by monkeys (35%) and dogs (22%). Only 4% of participants 
reported experience with FOB in minipigs.  A standalone study design was used by a majority 
(73%) of respondents (Table 2) and half (54%) of the participants had experience of adding the 
FOB to a toxicology study. When FOB evaluations were conducted after repeated dose 
administration, the most frequent time points evaluated excluding Day 1 were 7, 14 and 28 days 
after treatment onset including the last week of treatment. The most frequent FOB group size 
was n=8 (Figure 4). Respondents reported using study designs that included males only (52%) 
or males and females (53%) with females only used by 6% of participants. Most participants 
reported conducting FOB studies under GLP (50%) or both GLP and non-GLP (40%) (Table 3).  
FOB evaluations were often conducted in a dedicated room (78%), by blinded personnel (66%), 
with control for circadian cycle (55%) effects (e.g., dosing at a standardized time, or balancing 
time of day across treatment groups). Three dose levels had been used by two thirds (65%) of 
participants. A majority of respondents (79%) reported following the modified Irwin test rather 
than the FOB (Table 4). In contrast, only 9% reported using mazes or cognitive tests. The 
indication/drug class did not impact the type/extent of FOB/Irwin testing for 64%. For those that 
reported adjusting the type/extent of FOB/Irwin testing based on indication/drug class (36%), an 
increased level of testing was triggered by high blood brain barrier (BBB) permeability or CNS 
indications. Oncology drugs (i.e., ICH S9) and biologics (i.e., ICH S6) were generally viewed as 
requiring less extensive CNS testing. Statistical analysis was performed on all FOB data by 44% 
of participants and on selected parameters by 29%. The remainder, 27% did not undertake 
statistical analysis on FOB data (this probably refers to the incidence data).  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Authier et al 
2015 JPTM  
6/2/2016 
2.2.2 Seizure Liability Testing 
A majority (55%) of respondents to the survey had conducted or interpreted non-clinical seizure 
studies within the last 5 years. A minority (19%) of participants routinely conducted seizure 
studies during the early drug-screening phase of development. Conversely, 76% of participants 
conducted seizure studies based on results from other studies, and only 10% would terminate 
development of a compound when seizure liability is present. The therapeutic indication is likely 
to affect the decision taken in presence of a seizure liability but this was not evaluated in the 
current survey. A vehicle control (87%) and a positive control (53%) group were included by 
most participants in seizure liability studies (Table 5) but toxicokinetic (39%), cerebrospinal fluid 
(17%) and brain tissue (28%) samples were taken only by a minority of participants. The most 
frequent group size for seizure liability studies was n=8 (Figure 5). Fifteen percent of 
participants reported conducting all seizure liability assessments under GLP, 43% reported 
using GLP and non-GLP studies and 43% reported using non-GLP seizure liability studies only 
(Table 3). This presumably reflects that most seizure liability studies are conducted early in 
development. As a general principle, one would expect GLP work to be done later in 
development when candidates with easily identifiable liabilities have been excluded from further 
development. It appears that there are methods that can be used to identify drug candidates 
with seizure liabilities early in development before the need to conduct GLP arises (Löscher et 
al., 1991; Pollack & Shen, 1985). The rat was the most frequently used species with which to 
test the seizure potential (91%), followed by the mouse (47%) (Table 6). Similarly, rats (87%), 
dogs (45%), mice (39%) and monkeys (31%) were the most frequently used species when EEG 
recording was undertaken (Fig. 6). Implanted EEG electrodes (59%) and video monitoring 
(57%) were the most common methodology used followed by surface/cutaneous EEG (44%) 
(Table 7).  Manual seizure detection (62%) was used more commonly than automated detection 
(25%).  When implanted EEG electrodes were used, the anatomical plane in which the 
electrodes were implanted was approximately uniformly distributed between subcutaneous 
(35%), cortical bone (23%), surface of the dura mater (35%) and brain parenchyma (19%). 
When questioned on interpretation of seizure liability study data, 58% considered that historical 
data may be used to dismiss an animal with seizure after drug dosing, especially in dogs, and 
52% considered the Beagle dog as an appropriate species for seizure liability studies. The 
presence of clinical signs compatible with seizures needs to be interpreted in relation to drug 
administration and historical data may be considered to determine if the condition represents a 
background observation in the model irrespective of treatment or a consequence of dosing. 
Some participants suggested that pre-study EEG screening was required for Beagle dogs to 
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ensure suitability for the studies. A majority of participants (73%) considered that a safety 
margin of 10X to NOAEL for seizures was required while other participants considered 30X 
preferable, but a safety margin lower than 10X was also reported as acceptable in certain 
circumstances.  
2.2.3 Juvenile CNS Testing 
A majority (73%) of respondents had conducted or interpreted non-clinical juvenile CNS testing 
in the last 5 years. Rats (79%) and mice (32%) were the most common species used for 
juvenile CNS SP testing followed by non-human primates (24%) and dogs (15%) (Figure 7). 
This presumably reflects the stage in drug discovery and development in which the testing was 
undertaken (late stage, and lead candidate, reflected by use of larger mammals or primates). As 
expected, FOB was the most frequent (91%) juvenile CNS safety assay followed by memory 
tests (43%), learning tests (40%) and mazes (34%). The Morris water maze was the type most 
frequently (70%) reported.  
2.2.4 Polysomnography (Sleep) Studies 
Only 21% of participants had conducted or interpreted polysomnography studies in the previous 
5 years. A dose escalation design had been used by 42%, a cross over design by 39%, a repeat 
dose design had been used by 26%, and 42% of participants reported reusing animals in sleep 
studies. The dose group size used in these studies varied from 3-12, with n=8 reported to be 
used most frequently. Smaller group sizes were reported for larger species (i.e., non-human 
primates).  EEG (67%), video monitoring (53%), EMG (43%) and body temperature (43%) were 
the most frequently used parameters (Table 8). Sleep scoring was undertaken using automated 
(37%), manual (30%) or both (30%) methodologies.  
2.2.5 Peripheral Nerve Conduction Studies 
A minority of participants (28%) had conducted or interpreted peripheral nerve conduction 
studies in the last 5 years. Peripheral nerve conduction was added to a toxicology study by 54% 
while 49% conducted standalone studies. A repeat dose design (51%) was most frequent but a 
single dose (19%) or dose escalation (8%) designs were also reported for peripheral nerve 
function studies. Group size ranged from 6-20 and was reported to typically match the group 
size for the repeat dose toxicology study. Participants reported conducting peripheral nerve 
conduction studies under GLP (24%), non-GLP (38%) or both (38%) (Table 3). The rat was the 
most frequently reported species (72%) (Table 9) used for peripheral nerve conduction 
assessments. Nerve conduction velocity (68%) and histopathology (62%) were the most 
frequently selected parameters when conducting peripheral nerve toxicity tests (Table 10).  
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2.2.6 Drug Abuse Potential Studies 
Half (51%) of the participants had conducted or interpreted drug abuse potential studies in the 
previous 5 years. A typical group size of n=10 was reported for rats and 3-5 for non-rodents. 
When conducting standalone studies, self-administration (73%), drug withdrawal (47%) and 
drug discrimination (40%) were the most frequent study types reported by participants. Rat was 
the most common species (81%) used followed by non-human primate (38%), mouse (19%) 
and rabbit (6%).  
 
2.2.7 In Vitro Models of CNS Adverse Effects and Other Techniques  
In vitro models of CNS adverse effects had been used by a relatively limited proportion of 
participants. Hippocampal brain slice electrophysiology for seizure liability (30%), neuronal cell 
lines (27%), in vitro blood brain barrier models (20%), neuronal/glial co-culture (17%) and 
hippocampal brain slice electrophysiology for long-term potentiation (17%) were the most 
frequently reported models (Table 11). The larval zebrafish seizure assay (15%), stem cell 
derived neurons (14%) and brain slice electrophysiology studies using other brain regions (13%) 
were less commonly used (Table 11). 
3. Discussion 
The current survey aimed to identify current strategies for non-clinical drug SP testing as they 
relate to CNS adverse effects. Participants were distributed across four continents and 
originated from diverse company types and sizes.  Oncology and neurology were the most 
frequent indications for which new therapies were developed. The increasing size of the aging 
population is projected to double the incidence of CNS diseases by 2050 (Wright et al., 2010; 
Alzheimer's Association, 2015). Concurrently, mortalities from heart diseases, stroke and 
prostate cancer are expected to decline (Nowbar et al., 2014; Torre et al., 2015). In view of this, 
CNS adverse effect liability and testing for liability are likely to become more important since 
drugs for CNS indications (including psychiatric and neurological indications, as well as drugs 
targeting brain tumors and metastases) represent the broad class with the greatest risk of CNS 
adverse effect liability, because by nature these agents are CNS active and/or CNS penetrant.  
 
Seizure, gait abnormalities and tremors were the most frequent CNS issues detected in non-
clinical drug SP testing in the last 5 years. The incidence of seizures in the elderly population is 
estimated to be 10-fold higher than in adults (Elberly et al. 2010, Hauser et al., 1993). 
Susceptibility to drug induced seizures is generally increased in a population with a history of 
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seizure. Concomitantly, a majority of individuals over the age of 60 take more than three 
prescription drugs (Gu et al., 2010) supporting a positive correlation between age and the use of 
polypharmacy. The increasing incidence of seizures with age combined with the frequent use of 
prescription drugs in an older population places seizure liability testing in a critical position with 
respect to the risk for adverse drug reaction (ADR). Potentially fatal ADRs such as arrhythmias 
and seizure mandate a higher level of risk assessment. Drug induced seizures are important 
medical events with significant impact to patients and are also considered a serious adverse 
event owing to the potential for status epilepticus, a life-threatening condition that manifests as 
continuous or rapidly repeating seizures (Gastaut, 1970; Lowenstein et al., 1998). The incidence 
of status epilepticus has increased four-fold from 1979 to 2010 (Dham et al., 2014) with age 
considered as an important factor for mortality. Strategies to evaluate seizure liability represent 
an essential component of risk identification and management in the development of new 
therapies.   
 
The FOB/Irwin Test can capture a wide range of drug-induced CNS effects (Redfern et al., 
2005) and may be adapted to most laboratory animal species including rats (Himmel, 2008), 
mice (Irwin, 1968), minipigs (Giarola et al., 2008), dogs (Moscardo et al., 2009) and non-human 
primates (Gauvin & Baird, 2008; Moscardo et al., 2010; Authier et al., 2012). This survey 
identified the rat as the most frequently used species for FOB studies followed by mice, non-
human primates and dogs in approximately equivalent proportions. The abundant historical data 
in rats and the predominant use of rats as the rodent species for regulatory toxicology studies 
justifies its selection by default. Species selection is subjected to a plethora of other factors such 
as pharmacokinetics, metabolism and receptor affinity as well as genetic and phenotypic 
homology just to name a few. Most participants reported conducting FOB evaluations as 
standalone studies with three dose levels.  Half of the participants (54%) from the current survey 
reported experience with a design in which a FOB was added to toxicology studies. In a 
previous industry survey conducted in 2012 by the SPS, 34% of participants had experience 
with inclusion of FOB in toxicology studies (Authier et al., 2013), possibly indicating increasing 
experience with the study designs and/or increasing development of biotherapeutic agents over 
the last three years. When conducted by experienced groups, FOB/Irwin Test assessments 
were shown to be robust to identify CNS drug effects with known CNS-active agents (Porsolt et 
al., 2002; Moscardo et al., 2007; Redfern et al., 2005; Ewart et al., 2013), justifying the addition 
of CNS endpoints in toxicology studies, useful in a 3R‟s context (Redfern et al., 2013; Redfern, 
2015). A wide range of group sizes was reported (i.e. n=3 to 30), but a majority of respondents 
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used a design with n= 6 or n=8. FOB assessments conducted during early drug discovery are 
likely to be undertaken as non-GLP while evaluations done during clinical trial enabling studies 
will typically be completed according to GLP. Only a minority (12%) of participants indicated that 
FOB assessments were done only non-GLP, but a majority (90%) indicated that FOB 
evaluations were done under GLP only or both non-GLP and GLP.  
 
Statistical analysis on FOB data appears to be done much less (44%) frequently than one might 
anticipate. Although it may be perceived that the observational/qualitative nature of most 
variables makes analysis challenging, whether statistical analysis is permissible or not is 
primarily dependent on experimental design: adequate group sizes, randomization and blinding, 
in particular (Curtis & Abernethy, 2015; Curtis et al., 2015). Various established approaches 
may be used (Moscardo et al., 2007; Markgraf et al., 2010) to identify drug effects in FOB 
studies. Results from the current survey confirm that a majority of participants undertake 
statistical analysis (combined 74%), at least for some parameters.  For example, Redfern et al. 
(2005) and Ewart et al (2013) performed statistical analysis of their FOB continuous data and 
counts, but used a rule-based approach for their incidence data. In simple terms, incidence of 
an observed parameter was considered noteworthy if it occurred in 50% of the treatment group, 
the reason being that statistical significance of P<0.05 for group sizes of 6 (using Fisher‟s Exact 
Test) requires 5/6 rats to exhibit the effect.  Setting a lower threshold than this (ie, 3/6) is 
arguably prudent when in the business of hazard detection.  Statistical analysis is more 
appropriate when using a larger group size and when ranking the severity of the observed 
parameters, but even so, when Markgraf et al. (2010) compared two nonparametric statistical 
tests with a qualitative assessment of ranked observations and group sizes of 8, all three 
methods of analysis provided similar outcomes.  
 
Fifty-two (52) drugs for pediatric indications were approved by the FDA in the last decade 
(www.centerwatch.com; Accessed on September 23, 2015), representing an important area for 
pharmaceutical research.  A majority of respondents (73%) had experience with juvenile CNS 
testing and the FOB in young rats was reported as the most frequent assay used (91%). 
Pharmacological effects identified during FOB may differ between adult and juvenile animals 
(Himmel, 2008), justifying careful designs supported by regulatory guidance documents (EMEA, 
2008; FDA, 2006) to investigate possible neurotoxicity in a younger population when applicable.  
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A wide range of approved drugs are associated with drug induced sleep disturbances such as 
insomnia, including beta-blockers (Chang et al., 2013; Moser, 1979), corticosteroids (Ciriaco et 
al., 2013), selective serotonin-reuptake inhibitors (SSRI) (Asnis, et al., 1999) or 
acetylcholinesterase inhibitors (Cooke et al., 2006). Polysomnography is a well-established 
technique for sleep disturbance assessment and is well established in laboratory animal species 
commonly used for non-clinical drug SP testing including rodents (Gotter et al., 2013), dogs and 
non-human primates (Authier et al., 2014).  
 
The current survey highlights a high diversity in study designs and methodologies reflecting 
differences in therapeutic target and stage in the pipeline of drug development. For example, 
the impact of drug-induced sleep disturbance on drug success depends on the indication since 
more severe conditions (e.g., oncology) are considered less sensitivity to a potential change in 
sleep architecture given the severity of the disease and the shorter treatment period compared 
to other chronic conditions typically requiring lifelong therapies (e.g., diabetes, heart diseases, 
allergies, neurodegenerative diseases). Moreover, the impact of any adverse effect is entirely 
dependent on the therapeutic indication; for example, if a drug can treat cancer more effectively 
than any other, but has some adverse effects on sleep, the drug will be used, whereas if the 
indication is cough, it is not likely (Pugsley et al., 2008). More exhaustive non-clinical 
polysomnography studies are more likely to be undertaken for the non-life threatening 
indications for which drug induced sleep disturbances may have a more clinically relevant 
impact on the patient population. The tolerance for drug-induced undesired effects is recognized 
to increase with the severity of the disease that is treated (Pugsley et al., 2008).  
 
Peripheral neuropathies are a common limiting factor with oncology chemotherapeutic drugs 
(Quasthoff & Hartung, 2002; Wolf et al., 2008; Argyriou et al., 2007). Although the 
characterization of underlying mechanisms (Berg & Parsons et al., 2015; Bobylev et al., 2015; Li 
et al., 2015) is progressing and pharmacogenomic strategies are emerging (Gambarotta et al., 
2014), non-clinical electrophysiology models and behavioral assessments (mechanical allodynia 
and hyperalgesia) remain a cornerstone to identify drug-induced peripheral neuropathies. The 
rat is the most frequently used species for peripheral nerve function assessments. Rats were 
successfully used to identify peripheral neuropathy induced by chemotherapeutic drugs such as 
carboplatin (Cavaletti et al., 1998), cisplatin (Bianchi et al., 2006), paclitaxel (Cavaletti et al., 
1997) and vincristine (Alimoradi et al., 2012). Like any non-clinical model, the translational 
potential of peripheral nerve conduction tests remains imperfect. This is illustrated by 
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thalidomide which is associated with peripheral neuropathy in patients (Kocer et al., 2009) but 
failed to alter sensory nerve conduction velocity in a chronic toxicology study in Beagle dogs 
(Teo et al., 2000). Although it is often omitted, the reporting of both nerve conduction and 
histopathology findings should include the location of the points of assessments along a distal-
to-proximal gradient.  The absence of deficits measured at a relatively proximal site may yield a 
false negative finding in the presence of a “length-dependent distal axonopathy (Arezzo, J.C., et 
al., 2011).”  This is especially true for sensory neuropathies manifested in the elongated caudal 
nerve of the rat (Schaumburg et al., 2010). 
 
The current survey suggests that drug abuse liability was amongst the most frequent CNS 
follow-up SP studies conducted with 51% of the participants that had conducted or interpreted 
drug abuse potential studies in the last 5 years. As previously reported, drug abuse liability 
studies are conducted GLP or non-GLP (Moser et al., 2011). Robust scientific literature exists to 
support the use of rats for regulatory drug abuse liability studies (O‟Connor et al., 2011; Hudzik 
et al., 2013; Teuns et al., 2014) and this was echoed in the current survey in which a large 
majority (81%) of participants reported using this species. Amongst survey participants with 
experience in drug abuse liability testing, the three core pieces of behavioral data required in the 
overall abuse liability analysis (Ator & Griffiths, 2003) were the most frequently used (i.e., self-
administration (73%), drug withdrawal (47%) and drug discrimination (40%)). Participants 
reported a higher frequency of regulatory feedback on drug abuse liability studies when 
compared to other CNS drug safety testing areas.  Drug abuse liability studies are expected as 
part of the End of Phase 2 package for CNS-active drugs and therefore the high frequency of 
regulatory feedback is not unexpected. Furthermore, these well-defined studies are reported in 
the literature (Gauvin et al., 2015) and regulatory guidelines (EMEA, 2006; FDA, 2010), which 
can be used to support the study design rationale. 
4. Conclusion 
In conclusion, this industry survey conducted by the Safety Pharmacology Society (SPS) 
provides a snapshot of the current non-clinical CNS drug SP testing landscape. It confirms a 
number of well-accepted paradigms but also reveals study design trends for common follow-up 
models in CNS SP. Functional endpoints in CNS SP should exhibit high sensitivity and high 
translational value. Future non-clinical CNS industry surveys will reveal whether improvements 
have been made in this regard.  While this industry survey covered frequently used pre-clinical 
CNS safety testing models, the field is rapidly progressing with emerging considerations and 
assays such as neuropsychiatric liability, negative affective bias models, intracranial self-
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Authier et al 
2015 JPTM  
6/2/2016 
stimulation for anhedonia, microelectrode in vitro neuron network screening platforms or 
integrated safety assessments that take into consideration functional activity on CNS receptors 
that are identified during in vitro receptor profiling. Beyond the current survey, the Safety 
Pharmacology Society (SPS) plays an important role to unveil industry trends related to 
innovative functional drug safety testing strategies.  
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Figures 
Figure 1 – Central Nervous System Safety Pharmacology Investigations: Survey Demographics 
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Panel E 
 
Figure 1 – Panels A-E describe the characteristics of those responding to the survey in terms of 
expertise (A), geographical location (B), organization affiliation (Pharmaceutical, Biotechnology, 
Biopharmaceutical, Consultancy), size of the organization (D) and indication most frequently 
targeted by drugs developed from 2010 to 2015 (E). 
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Figure 2  
 
 
 
Figure 2: Types of CNS issues encountered in preclinical studies from 2010 to 2015. Emesis 
was included in the broad list of drug-induced neurological issues as it can originate from CNS 
or non-CNS etiologies. 
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Figure 3 
 
 
 
Figure 3: Types of CNS issues encountered in Phase I clinical trials from 2010 to 2015. 
Although emesis/nausea and fatigue are not typically considered CNS issues from a clinical 
adverse event terminology perspective, they have been included in this assessment due to the 
notion that the event reporting requires the element of perception that is under CNS control. 
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Figure 4 
 
 
Figure 4: Typical group size in functional observation battery (FOB) studies.   
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Figure 5.  
 
 
Figure 5: Typical group size in non-clinical seizure liability studies. 
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Figure 6. Species used in seizure liability studies.  
 
 
 
 
Figure 7. Species used in juvenile non-clinical CNS safety studies. 
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Figure 8. Study types for drug abuse liability studies.  
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Tables 
 
Table 1 Species in which FOB/Irwin test are conducted 
 
In which species are FOB/Irwin conducted?* 
Answer Options 
Response 
Percent 
Response 
Count 
Mice 36% 49 
Rats 96% 130 
Guinea pigs 1% 1 
Rabbits 1% 1 
Dogs 22% 30 
Monkeys 35% 47 
Minipigs 4% 6 
* Participants selected all that applied.  
 
 
 
 
 
 
 
 
 
Table 2 Study design characteristics when conducting FOB Assessments 
 
Please define FOB/Irwin study design used in your organization?* 
Answer Options 
Response 
Percent 
Response 
Count 
Standalone study 73% 118 
Added to a toxicology study 54% 87 
Evaluation after a single dose administration 59% 95 
Three dose levels 65% 106 
Dose escalating design (i.e. increasing dose levels to the same 
animals) 
12% 19 
Repeated dose administration (i.e. multiple days of treatment at the 
same dose level followed by FOB/Irwin test) 
40% 64 
* Participants selected all that applied.  
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Table 3. Quality standards used for FOB, seizure liability, peripheral nerve safety and drug-
abuse liability studies  
 
In your organization, are FOB/Irwin studies typically conducted under 
GLP? 
Answer Options 
Response 
Percent 
Response 
Count 
Yes 50% 64 
No 12% 15 
Both GLP and Non-GLP 40% 51 
In your organization, are seizure liability studies conducted under GLP? 
Answer Options 
Response 
Percent 
Response 
Count 
Yes 15% 11 
No 43% 31 
Both GLP and Non-GLP 43% 31 
In your organization, are peripheral nerve safety testing studies 
conducted under GLP? 
Answer Options 
Response 
Percent 
Response 
Count 
Yes 24% 9 
No 38% 14 
Both GLP and Non-GLP 38% 14 
In your organization, are drug abuse liability testing conducted under 
GLP? 
Answer Options 
Response 
Percent 
Response 
Count 
Yes 22% 4 
No 44% 8 
Both GLP and non-GLP 33% 6 
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Table 4. Parameters commonly included in FOB/Irwin studies 
 
Which tests were commonly included in FOB/Irwin studies at your 
organization?* 
Answer Options 
Response 
Percent 
Response 
Count 
We follow the Modified Irwin test 79% 95 
Rectal temperature 67% 81 
Open field (Gait/coordination, Number of 
urination/defecation, Number of rearings) 
73% 88 
Pupillary light response 55% 66 
Maze/cognitive tests 9% 11 
Landing foot splay 41% 49 
Rotarod 26% 32 
Grip strength 60% 73 
* Participants selected all that applied.  
 
 
Table 5. Seizure liability study designs 
 
Which study design have you used for seizure liability testing?* 
Answer Options 
Response 
Percent 
Response 
Count 
We include a vehicle control group 87% 65 
We include test article groups only 21% 16 
We include a PTZ threshold test 61% 46 
We use an electroshock seizure (ECS) threshold test 20% 15 
We include a positive control group (i.e. proconvulsant) in the PTZ or ECS 
threshold test 
53% 40 
We use repeated dose design 33% 25 
We collect TK sample, please specify 39% 29 
We collect cerebrospinal fluid (CSF) 17% 13 
We collect brain tissues 28% 21 
I do not know 8% 6 
* Participants selected all that applied.  
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Table 6. Species used for seizure liability studies 
Which species were used for seizure testing?* 
Answer Options 
Response 
Percent 
Response 
Count 
Mice 47% 35 
Rats 91% 67 
Guinea pigs 1% 1 
Rabbits 0% 0 
Dogs 37% 27 
Monkeys 24% 18 
Minipigs 0% 0 
* Participants selected all that applied.  
 
Table 7. Electrophysiological methodologies for seizure liability studies 
 
Which electrophysiological methodologies were used for seizure 
testing?* 
Answer Options 
Response 
Percent 
Response 
Count 
Surface EEG (on skin) 44% 30 
Implanted EEG 59% 40 
Surface EMG (on skin) 12% 8 
Implanted EMG 27% 18 
Telemetry 50% 34 
Video 57% 39 
Spectral analysis of EEG (qEEG) 31% 21 
Automated seizure detection 25% 17 
Manual seizure detection 62% 42 
* Participants selected all that applied.  
 
 
Table 8. Parameters evaluated in polysomnography (sleep) studies. 
 
Which parameters were evaluated in non-clinical sleep studies?* 
Answer Options 
Response 
Percent 
Response 
Count 
EEG (electroencephalography) 67% 20 
EMG (electromyography) 43% 13 
EOG (electro-oculography) 23% 7 
Video monitoring 53% 16 
Activity pattern (beam break, accelerometer, 
open field) 
37% 11 
Body temperature 43% 13 
* Participants selected all that applied.  
 
 
 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
Authier et al 
2015 JPTM  
6/2/2016 
Table 9. Species used for peripheral nerve safety studies.  
 
Which species were used in peripheral nerve safety testing studies?* 
Answer Options 
Response 
Percent 
Response 
Count 
Mice 31% 11 
Rats 72% 26 
Guinea pigs 0% 0 
Rabbits 8% 3 
Dogs 31% 11 
Monkeys 31% 11 
Minipigs 0% 0 
* Participants selected all that applied.  
 
Table 10. Parameters used for peripheral nerve safety studies.  
 
Which parameters were evaluated in peripheral nerve safety testing 
studies (Select all that apply)?* 
Answer Options 
Response 
Percent 
Response 
Count 
Nerve conduction velocity 68% 23 
Grip strength 32% 11 
Motor coordination 44% 15 
Nociception 32% 11 
Allodynia (e.g. von Frey meter) 38% 13 
Histopathology 62% 21 
* Participants selected all that applied.  
 
 
Table 11. In vitro and other techniques for CNS safety assessment 
 
Have you used any of the following in vitro techniques in the last 5 years?* 
Answer Options Yes No 
Response 
Count 
Hippocampal brain slice electrophysiology: 
seizure liability 
30 75 105 
Hippocampal brain slice electrophysiology: 
long-term potentiation 
17 83 100 
Brain slice electrophysiology – other brain 
region 
13 84 97 
Neuronal cell line 27 74 101 
Neuronal/glial co-culture 17 81 98 
Stem cell derived neurons 14 82 96 
In vitro blood-brain barrier 20 79 99 
Larval zebrafish seizure assay 15 84 99 
Larval zebrafish ototoxicity assay 3 94 97 
* Participants selected all that applied.  
